Prescribing patterns in dementia: A multicentre observational study in a German network of CAM physicians

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Jeschke, Elke ^a   Ostermann, Thomas ^b   Vollmar, Horst C ^b,c   Tabali, Manuela ^a   Schad, Friedemann ^a   Matthes, Harald ^a  

^a Havelhoehe Research Institute   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; BUTYROPHENONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ERGOT ALKALOID; GALANTAMINE; GINKGO BILOBA EXTRACT; HYPNOTIC AGENT; MEMANTINE; NEUROLEPTIC AGENT; NIMODIPINE; NOOTROPIC AGENT; PIRACETAM; RISPERIDONE; RIVASTIGMINE; SEDATIVE AGENT; SELEGILINE;

ADULT; AGED; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DEMENTIA; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; GENERAL PRACTITIONER; GERMANY; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTIINFARCT DEMENTIA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PARKINSON DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; SEX DIFFERENCE; AGE; CLINICAL PROTOCOL; CLINICAL TRIAL; GINKGO BILOBA; MULTICENTER STUDY; PHYTOTHERAPY; PRIMARY HEALTH CARE; STATISTICS;

AGE FACTORS; AGED, 80 AND OVER; CLINICAL PROTOCOLS; COMPLEMENTARY THERAPIES; DEMENTIA; FEMALE; GERMANY; GINKGO BILOBA; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PHYTOTHERAPY; PRIMARY HEALTH CARE; SEX FACTORS;

EID: 79961110204     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-99     Document Type: Article

References (51)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117. 2850264, 16360788.
2. Deutsche Alzheimer Gesellschaft e.V.: Die Epidemiologie der Demenz. , http://www.deutsche-alzheimer.de/fileadmin/alz/pdf/factsheets/FactSheet01.pdf
3. Wimo A, Prince M. World Alzheimer Report 2010: the global economic impact of dementia. Alzheimer's Disease International. 2010, http://www.alz.org/documents/national/World_Alzheimer_Report_2010_Summary(1).pdf
4. Krankheitskosten: Deutschland, Fachserie 12 Reihe 7.2. Statistisches Bundesamt: Gesundheit 2010, http://www.gbe-bund.de/gbe10/owards.prc_show_pdf?p_id=13548&p_sprache=d&p_uid=&p_aid=&p_lfd_nr=1
5. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, CD005593.
6. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006, CD003154.
7. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008, 148:379-397.
8. Kaduszkiewicz H, Hoffmann F. Review: cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia. Evid Based Ment Health 2008, 11:113. 10.1136/ebmh.11.4.113, 18952962.
9. May BH, Lit M, Xue CC, Yang AW, Zhang AL, Owens MD, Head R, Cobiac L, Li CG, Hugel H, Story DF. Herbal medicine for dementia: a systematic review. Phytother Res 2009, 23:447-459. 10.1002/ptr.2656, 19086008.
10. McCarney R, Warner J, Fisher P, Van Haselen R. Homeopathy for dementia. Cochrane Database Syst Rev 2003, CD003803.
11. Li XJ, Zhang HY. Potential anti-dementia agents in traditional Chinese medicine. Nat Prod Commun 2009, 4:877-886.
12. Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE. Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder. Epilepsia 2006, 47:323-329. 10.1111/j.1528-1167.2006.00424.x, 16499756.
13. Schwabe U. [Antidementiva]. Arzneiverordnungsreport 2007 2008, 313-316. Heidelberg: Springer Medizin Verlag, Schwabe U, Paffrath D.
14. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007, CD003120.
15. Baurle P, Suter A, Wormstall H. Safety and effectiveness of a traditional ginkgo fresh plant extract - results from a clinical trial. Forsch Komplementmed 2009, 16:156-161. 10.1159/000213167, 19657199.
16. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 2010, 10:14. 10.1186/1471-2318-10-14, 2846949, 20236541.
17. Ginkgohaltige Präparate bei Alzheimer Demenz. Final-Report. IQWIG 2008, http://www.iqwig.de/download/A05-19B_Abschlussbericht_Ginkgohaltige_Praeparate_bei_Alzheimer_Demenz.pdf
18. Vollmar HC, Mand P, Butzlaff ME. [Demenz DEGAM-Leitlinie Nr.12]. Düsseldorf: Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) 2008, http://leitlinien.degam.de/index.php?id=247
19. Psychotherapie und Nervenheilkunde: S3- Leitlinie Demenzen. Deutsche Gesellschaft für Neurologie und Deutsche Gesellschaft für Psychiatrie 2009, http://www.dgn.org/images/stories/dgn/leitlinien/ll_demenz/ll-demenz-lang-170210.pdf
20. Vollmar HC, Abholz HH, Egidi G, Wilm S. [Quo Vadis Dementia? Similarities and Differences Between Specialist and Family Medicine Guideline]. Zeitschrift für Allgemeinmedizin 2010, 86:41-53.
21. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999, 282:1458-1465. 10.1001/jama.282.15.1458, 10535437.
22. Freeborn DK, Shye D, Mullooly JP, Eraker S, Romeo J. Primary care physicians' use of lumbar spine imaging tests: effects of guidelines and practice pattern feedback. J Gen Intern Med 1997, 12:619-625. 10.1046/j.1525-1497.1997.07122.x, 1497173, 9346458.
23. Schers H, Wensing M, Huijsmans Z, van Tulder M, Grol R. Implementation barriers for general practice guidelines on low back pain a qualitative study. Spine 2001, 26:E348-353. 10.1097/00007632-200108010-00013, 11474367.
24. Espeland A, Baerheim A. Factors affecting general practitioners' decisions about plain radiography for back pain: implications for classification of guideline barriers--a qualitative study. BMC Health Serv Res 2003, 3:8. 10.1186/1472-6963-3-8, 153534, 12659640.
25. van den Bussche H, Kaduszkiewicz H. [Prescription patterns and effectiveness perception of anti-dementia drugs - A comparison between General Practitioners, Neurologists and Psychiatrists]. Nervenheilkunde 2005, 485-492.
26. Matthes H, Tabali M, Jeschke E. Ein Pharmakovigilanzsystem für Arzneimittel der besonderen Therapierichtungen. EHK 2008, 34-39.
27. Jeschke E, Ostermann T, Lüke C, Tabali M, Kröz M, Bockelbrink A, Witt MC, Willich SN, Matthes H. Remedies Containing Asteraceae Extracts: A Prospective Observational Study of Prescribing Patterns and Adverse Drug Reactions in German Primary Care. Drug Saf 2009, 32:1-16. 10.2165/00002018-200932010-00001, 19591533.
28. Jeschke E, Ostermann T, Tabali M, Bockelbrink A, Witt CM, Willich SN, Matthes H. Diagnostic profiles and prescribing patterns in everyday anthroposophic medical practice--a prospective multi-centre study. Forsch Komplementmed 2009, 16(5):325-333. 10.1159/000235239, 19887811 .
29. , . Arbeitsgruppe Erhebung und Nutzung von Sekundärdaten der Deutschen Gesellschaft für Sozialmedizin und Prävention, Arbeitsgruppe Epidemiologische Methoden der Deutschen Gesellschaft für Epidemiologie, Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie, Deutschen Gesellschaft für Sozialmedizin und Prävention. [Good practice of secondary data analysis, first revision]. Gesundheitswesen 2008, 70:54-60. Arbeitsgruppe Erhebung und Nutzung von Sekundärdaten der Deutschen Gesellschaft für Sozialmedizin und Prävention, Arbeitsgruppe Epidemiologische Methoden der Deutschen Gesellschaft für Epidemiologie, Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie, Deutschen Gesellschaft für Sozialmedizin und Prävention. .
30. Jeschke E, Schad F, Pissarek J, Matthes B, Albrecht U, Matthes H. [QuaDoSta - ein frei konfigurierbares System zur Unterstützung multizentrischer Datenerhebungen in medizinischer Versorgung und Forschung]. GMS Med Inform Biom Epidemiol 2007, 3:Doc10.
31. Kassenärztliche Bundesvereinigung: Grunddaten zur vertragsärztlichen Versorgung. 2008. , http://www.kbv.de/publikationen/2394.html
32. Olsson J, Bergman A, Carlsten A, Oke T, Bernsten C, Schmidt IK, Fastbom J. Quality of drug prescribing in elderly people in nursing homes and special care units for dementia: a cross-sectional computerized pharmacy register analysis. Clin Drug Investig 2010, 30:289-300. 10.2165/11534320-000000000-00000, 20384385.
33. Koller D, Eisele M, Kaduszkiewicz H, Schon G, Steinmann S, Wiese B, Glaeske G, van den Bussche H. Ambulatory health services utilization in patients with dementia - Is there an urban-rural difference?. Int J Health Geogr 2010, 9:59. 10.1186/1476-072X-9-59, 2999610, 21083894.
34. [Die Demenzerkrankung - psychologische und medizinische Aspekte]. Landesverband der Alzheimer-Gesellschaften Nordrhein-Westfalen e.V. , http://www.alzheimer-nrw.de/files/downloads/%DCbersicht%20Demenz.pdf
35. Formiga F, Fort I, Robles MJ, Riu S, Sabartes O, Barranco E, Catena J. Comorbidity and clinical features in elderly patients with dementia: differences according to dementia severity. J Nutr Health Aging 2009, 13:423-427. 10.1007/s12603-009-0078-x, 19390748.
36. Frisoni GB, Canu E, Geroldi C, Brignoli B, Anglani L, Galluzzi S, Zacchi V, Zanetti O. Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy. Aging Clin Exp Res 2007, 19:349-355.
37. Stoppe G, Pirk O, Haupt M. [Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?]. Gesundheitswesen 2005, 67:20-26. 10.1055/s-2004-813937, 19591533.
38. Hoffmann F, van den Bussche H, Glaeske G, Kaduszkiewicz H. Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. Int Clin Psychopharmacol 2010, 25:29-36. 10.1097/YIC.0b013e3283339496, 19934763.
39. Truter I. Prescribing of drugs for Alzheimer's disease: a South African database analysis. Int Psychogeriatr 2010, 22:264-269. 10.1017/S1041610209991530, 20067653.
40. Formiga F, Fort I, Robles MJ, Rodriguez D, Regalado P. Lower barthel index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease. Dement Geriatr Cogn Disord 2010, 29:198-203. 10.1159/000278348, 20332637.
41. Ruof J, Mittendorf T, Pirk O, von der Schulenburg JM. Diffusion of innovations: treatment of Alzheimer's disease in Germany. Health Policy 2002, 60:59-66. 10.1016/S0168-8510(01)00191-9, 11879945.
42. Nahin RL, Fitzpatrick AL, Williamson JD, Burke GL, Dekosky ST, Furberg C. Use of herbal medicine and other dietary supplements in community-dwelling older people: Baseline data from the ginkgo evaluation of memory study. J Am Geriatr Soc 2006, 54:1725-1735. 10.1111/j.1532-5415.2006.00942.x, 17087700.
43. Hillmer M, Krahn M, Pariser P, Naglie G. Prescribing patterns for Alzheimer disease: survey of Canadian family physicians. Can Fam Physician 2006, 52:208-209. 1479726, 16926965.
44. Windfuhr K, Turnbull P, While D, Swinson N, Mehta H, Hadfield K, Hiroeh U, Watkinson H, Dixon C, Flynn S, et al. The incidence and associated risk factors for sudden unexplained death in psychiatric in-patients in England and Wales. J Psychopharmacol 2010,
45. Meyer G, Köpke S, Haastert B, Mühlhauser B. Restraint use among nursing home residents: cross-sectional study and prospective cohort study. Journal of Clinical Nursing 2009, 981-990.
46. Molter-Bock E, Hasford J, Pfundstein T. [Psychopharmacological drug treatment in Munich nursing homes]. Z Gerontol Geriatr 2006, 39:336-343. 10.1007/s00391-006-0401-7, 17039288.
47. Mann E, Kopke S, Haastert B, Pitkala K, Meyer G. Psychotropic medication use among nursing home residents in Austria: a cross-sectional study. BMC Geriatr 2009, 9:18. 10.1186/1471-2318-9-18, 2697155, 19460135.
48. Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging 2003, 20:437-444. 10.2165/00002512-200320060-00003, 12710863.
49. Mann JL, Evans TS, Taylor RD, Hettich LA, Kildsig N, Simcox D, McKinley WM. The use of medications with known or potential anticholinergic activity in patients with dementia receiving cholinesterase inhibitors. Consult Pharm 2003, 18:1042-1049.
50. Modi A, Weiner M, Craig BA, Sands LP, Rosenman MB, Thomas J. Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. J Am Geriatr Soc 2009, 57:1238-1244. 10.1111/j.1532-5415.2009.02258.x, 19467148.
51. Robinson M, Rowett D, Leverton A, Mabbott V. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiol Drug Saf 2009, 18:659-664. 10.1002/pds.1739, 19548222.